María Saumoy

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study

Estebán Martínez, María Larrousse, Josep M. Llibre et al. · AIDS · 2010 · 192 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial

José Ramón Santos, María Saumoy, Adrián Curran et al. · Clinical Infectious Diseases · 2015 · 140 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +5

Delayed Diagnosis of HIV Infection in a Multicenter Cohort: Prevalence, Risk Factors, Response to HAART and Impact on Mortality

Paz Sobrino‐Vegas, Lucía García San Miguel, Ana M. Caro- Murillo et al. · Current HIV Research · 2009 · 113 citations

Public Health, Health Sciences, Infectious Diseases +16

Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study

Daniel K. Nomah, Juliana Reyes‐Urueña, Yesika Díaz et al. · The Lancet HIV · 2021 · 110 citations · Full text

Public Health, Health Sciences, Infectious Diseases +17

In Vitro Cytotoxicity and Mitochondrial Toxicity of Tenofovir Alone and in Combination with Other Antiretrovirals in Human Renal Proximal Tubule Cells

Francesc Vidal, Joan Carles Domingo, Jordi P Guallar et al. · Antimicrobial Agents and Chemotherapy · 2006 · 71 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17